Skip to main content
SpringerLink
Log in

Potential uses of interferon α2 as adjuvant therapy in cancer

  • Educational Review
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: The purpose of this study was to provide an overview of the potential uses of adjuvant interferon (IFN) therapy for resected solid tumors at high risk for postsurgical relapse.

Methods: A MEDLINE search (1970–1994) of the English-language literature for original articles, reviews, and abstracts addressing IFN use in the adjuvant setting together with the authors' collective experience formed the basis for this review.

Results: The use of adjuvant IFN-α has been studied most extensively in conjunction with the treatment of melanoma. Fewer data are available on IFN-α use for the treatment of other solid tumors. In melanoma, there is evidence from Intergroup trials (Eastern Cooperative Oncology Group and World Health Organization) that IFN-α2a given for 1–3 years prolongs the interval to relapse and may have a survival benefit. Trials of adjuvant IFN, with and without chemotherapy, are ongoing in the treatment of renal cell carcinoma and colorectal adenocarcinoma. Its value in the treatment of osteosarcoma and high-grade astrocytoma is unknown.

Conclusions: The use of IFN in the adjuvant setting is an exciting area of medical and surgical oncology and has the potential to prolong the time to relapse and to increase survival of patients with melanoma. Its role in the adjuvant therapy of other solid tumors remains to be defined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Isaacs A, Lindemann JJ. Virus interference: the interferon.Proc R Soc Lond 1957;147:258–67.

    CAS  Google Scholar 

  2. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer.J Clin Oncol 1984;2:336–52.

    CAS  PubMed  Google Scholar 

  3. Clemens MJ. Molecular mechanisms of interferon action (Abstract).Br J Clin Pract Symp Suppl 1988;62:5–12.

    CAS  PubMed  Google Scholar 

  4. Banerjee D, Baksi K, Friedman RM. Interferon-mediated inhibition of adenylate cyclase in mouse cells.J Interferon Res 1982;2:501–10.

    CAS  PubMed  Google Scholar 

  5. Levy DE, Kessler DS, Pine R, Darnell JE Jr. Cytoplasmic activation of ISGF3, the positive receptor of interferon-α-stimulated transcription, reconstituted in vitro.Genes Dev 1989;3:1362–71.

    CAS  PubMed  Google Scholar 

  6. Klapdor R, Bahlo M, Schwarzenbeck O, Hirschmann M. Immunotherapy of pancreatic carcinomas (PACA) with the monoclonal antibody BW 494/32 (Abstract).Br J Cancer 1987;56:527–8.

    Google Scholar 

  7. Goodenow RS, Vogel JM, Linsk RL. Histocompatibility antigens on murine tumors.Science 1985;230:777–83.

    CAS  PubMed  Google Scholar 

  8. Haque SJ, Williams BR. Identification and characterization of an interferon (IFN)-stimulated response element-IFN-stimulated gene factor 3-independent signaling pathway for IFN-alpha.J Biol Chem 1994;269:19523–9.

    CAS  PubMed  Google Scholar 

  9. Murray JL, Stuckey SE, Pillow JK, Rosenblum MG, Gutterman JU. Differential in vitro effects of recombinant α-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens.J Biol Resp Mod 1988;7:152–161.

    CAS  Google Scholar 

  10. Imai K, Ng A, Glassy MC, et al. Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship of susceptibility to immune lysis mediated by monoclonal antibodies.J Immunol 1981;127:505–9.

    CAS  PubMed  Google Scholar 

  11. Fellous M, Nir U, Wallach D, Merlin G, Rubinstein M, Revel M. Interferon-dependent induction on mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells.Proc Natl Acad Sci U S A 1982;79:3082–6.

    CAS  PubMed  Google Scholar 

  12. Giedlund MA, Orn H, Wigzell H, et al. Enhanced NK cell activity in mice injected with interferon and interferon inducers.Nature 1987;273:759–63.

    Google Scholar 

  13. Teichmann JV, Sieber G, Ludwig W-D, et al. Immunosuppressive effects of recombinant interferon-α during long-term treatment of cancer patients.Cancer 1989;63:1990–3.

    CAS  PubMed  Google Scholar 

  14. Sala A, Gresser I, Chassoux D, et al. Inhibition of Friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action.Cancer Res 1992;52:2880–9.

    CAS  PubMed  Google Scholar 

  15. Kaido T, Gresser I, Maury C, Maunoury MT, Vignoux F, Belardelli F. Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN alpha/beta therapy of Friend erythroleukemia visceral metastases.Int J Cancer 1993;54:475–81.

    CAS  PubMed  Google Scholar 

  16. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice.J Natl Cancer Inst 1989;81:497–502.

    CAS  PubMed  Google Scholar 

  17. Folkman J. Successful treatment of an angiogenic disease.N Engl J Med 1989;320:1211–2.

    CAS  PubMed  Google Scholar 

  18. Ezekowitz RAB, Phil D, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.N Engl J Med 1992;326:1456–63.

    CAS  PubMed  Google Scholar 

  19. Riegel DS, Kopf AN, Friedman RJ. The rate of malignant melanoma in the US: are we making an impact?J Am Acad Dermatol 1987;17:1050.

    Google Scholar 

  20. Balch CM, Soong S, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia.Ann Surg 1982;196:677–84.

    CAS  PubMed  Google Scholar 

  21. Balch CM, Soong S, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II).Ann Surg 1981;193:377–88.

    CAS  PubMed  Google Scholar 

  22. Kirkwood JM, Agarwala S. Systemic cytotoxic and biologic therapy melanoma.PPO Updates 1993;7:1–16.

    Google Scholar 

  23. Thompson JA, Cox WW, Lindgren CG, Collins C, Neraas KA, Fefer A. A phase I trial of recombinant interleukin 2: toxicity, pharmacokinetics, and immunomodulatory effects.Cancer Res 1987;47:4202–7.

    CAS  PubMed  Google Scholar 

  24. Creagan ET, Ahmann DL, Green SJ, et al. Phase II study of recombinant leukocyte A interferon (rIFN-αA) in disseminated malignant melanoma.Cancer 1984;54:2844–9.

    CAS  PubMed  Google Scholar 

  25. Kokoschka E-M, Trautinger F, Knobler RM, Pohl-Markl H, Micksche M. Long-term adjuvant therapy of high-risk malignant melanoma with interferon α2b.J Invest Dermatol 1990;95(suppl):193–7.

    Google Scholar 

  26. Kirkwood J, Hunt M, Smith T, Ernstoff M, Borden E, Blum R. A randomized controlled trial of high-dose IFN alfa-2b for high-risk melanoma: the ECOG trial EST-1684 [Abstract].Proc Am Soc Clin Oncol 1993;12:390.

    Google Scholar 

  27. Cascinelli N, Bufalino R, Morabito A, MacKie R. Results of adjuvant interferon study in WHO melanoma programme.Lancet 1994;343:913–4.

    Article  CAS  PubMed  Google Scholar 

  28. Gutterman JU, Blumenschein GR, Alexanian R, et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma.Ann Intern Med 1980;93:399–405.

    CAS  PubMed  Google Scholar 

  29. Sarna GP, Figlin RA. Phase II trial of alpha lymphoblastoid interferon given weekly as a treatment of advanced breast cancer.Cancer Treat Rep 1985;69:547–9.

    CAS  PubMed  Google Scholar 

  30. Martin J, McKibben B, van den Berg HW. Interferon alpha receptor expression by human breast cancer cells (Abstract).Br J Cancer 1990;62:531.

    Google Scholar 

  31. Seymour L, Bezwoda WR. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.Br J Cancer 1993;68:352–6.

    CAS  PubMed  Google Scholar 

  32. Sica G, Iacopino F, Lama G, et al. Steroid receptor enhancement by natural interferon-beta in advanced breast cancer (Abstract).Eur J Cancer 1993;29:329–33.

    Article  Google Scholar 

  33. Herberman RB, Ernstoff MS, Kirkwood JM. Interferon alpha in combination with other biologics: the scientific rationale.Br J Haematol 1991;79(suppl 1):78–80.

    CAS  PubMed  Google Scholar 

  34. Fentiman IS, Balkwill FR, Cuzick J, Hayward JL, Rubens RD. A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence.Eur J Surg Oncol 1987;13:425–8.

    CAS  PubMed  Google Scholar 

  35. Buzdar AU, Hortobagyi GN, Kau SC, et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamde with or without leukocyte alfa-interferon for stage II or III breast cancer.J Clin Oncol 1992;10:1540–6.

    CAS  PubMed  Google Scholar 

  36. Porzsolt F. Adjuvant therapy of renal cell cancer (rcc) with interferon alpha-2a [Abstract].Proc Am Soc Clin Oncol 1992;11:622.

    Google Scholar 

  37. Chu E, Zinn S, Boarman D, Allegra CJ. Interaction of gamma-interferon and 5-fluorouracil in the H630 human colon carcinoma cell line.Cancer Res 1990;50:5834–40.

    CAS  PubMed  Google Scholar 

  38. Elias L, Sandoval JM. Interferon effects upon fluorouracil metabolism by HL-60 cells.Biochem Biophys Res Commun 1989;163:867–74.

    Article  CAS  PubMed  Google Scholar 

  39. Wadler S, Wiernik PH. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma.Semin Oncol 1990;17(suppl 1):16–21.

    CAS  PubMed  Google Scholar 

  40. Pazdur R, Ajani JA, Patt YZ, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.J Clin Oncol 1990;8:2027–2031.

    CAS  PubMed  Google Scholar 

  41. Papacostas P, Stathopoulos GP, Samelis G, et al. Toxicity of 5-fluorouracil, leucovorin plus/minus interferon-a combination in adjuvant treatment of colorectal cancer..Ann Oncol 1992;3(suppl 5):17.

    Google Scholar 

  42. Brouty-Boye D, Wybier-Franqui J, Nardeux P, Daya-Grosjean L, Andeol Y, Suarez HG. Interferon-induced phenotypic changes in human tumor cells relative to the effects of interferon on c-ras oncogene expression.J Interferon Res 1986;6:461–71.

    CAS  PubMed  Google Scholar 

  43. Strander H, Bauer HCF, Brosjö O, et al. Adjuvant interferon treatment in human osteosarcoma. In: Humphrey GB, ed.Osteosarcoma in adolescents and young adults. Boston, MA: Kluwer Academic, 1993:29–32.

    Google Scholar 

  44. Fine HA, Wen P, Alexander E, Black PM, Loeffler JS. Alpha interferon, BCNU and 5-fluorouracil (5-FU) in the treatment of recurrent high-grade astrocytomas [Abstract].Proc Am Soc Clin Oncol 1993;12:495.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Division of Medical Oncology, University of Pittsburgh and Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA

    Sanjiv S. Agarwala MD & John M. Kirkwood MD

Authors
  1. Sanjiv S. Agarwala MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John M. Kirkwood MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agarwala, S.S., Kirkwood, J.M. Potential uses of interferon α2 as adjuvant therapy in cancer. Annals of Surgical Oncology 2, 365–371 (1995). https://doi.org/10.1007/BF02307071

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02307071

Key Words

Search

Navigation